Mizuho Strategist: Healthcare Is Now a Value Sector as Pharma Stocks Underperform Tech

Healthcare is being framed as a value-oriented offset to crowded AI and mega-cap growth positions, with Jared Holz arguing that years of underperformance have made the sector more attractive on relative valuations. Merck stands out as the higher-quality idea: forward P/E of 23, 2.74% dividend yield, Q1 2026 revenue of $16.29B vs. $15.82B expected, and raised 2026 guidance to $65.8B-$67.0B revenue and $5.04-$5.16 non-GAAP EPS. Summit Therapeutics is the higher-risk catalyst play, with shares down 13.75% over the past year, $598.7M in cash, a $114.7M quarterly burn, and an FDA PDUFA decision on ivonescimab due November 14, 2026.

Analysis

Healthcare’s setup here is less about an imminent sector rerating and more about factor rotation mechanics. If portfolios are crowded into AI/growth, the first marginal bid into defensives will likely go to cash-generative large caps with visible pipelines and shareholder returns, which means the sector can outperform even without a true fundamental inflection. That makes the trade more durable on a relative basis than on an absolute basis: the upside comes from being under-owned, not from a sudden earnings acceleration.

MRK is the cleaner expression because the market already knows the near-term risk profile, but the franchise concentration cuts both ways. When a single asset effectively underwrites the equity, the stock can trade like a bond-proxy until any sign of durability or loss-of-exclusivity anxiety shifts sentiment; in the meantime, the dividend and buyback capacity should compress downside unless guidance slips. The more interesting second-order effect is on adjacent oncology names: if the market keeps rewarding backbone therapies over speculative monotherapies, smaller developers may need to partner earlier and on worse terms, which favors large-cap pharma licensors over standalone biotechs.

SMMT is a binary catalyst trade, but the market is really pricing a geography and reproducibility discount, not just clinical data. The key risk is that even good readouts may not translate into a de-rating event if investors remain anchored to the idea that China-generated efficacy is not enough for Western commercialization; that can cap multiple expansion until regulatory clarity. A negative FDA outcome would likely reprice the story sharply within days, while a clean approval could still produce a multi-month rerating if commercial language improves, but the base rate remains lower than the implied analyst target suggests.

The contrarian point is that healthcare may not need to be "cheap" in an absolute sense to work as a hedge; it only needs earnings visibility to look less uncertain than long-duration tech. If that framing spreads, capital could rotate into healthcare as a temporary parking lot rather than a conviction overweight, which would support the group for months even without broad enthusiasm.

Key Decisions for Investors

• Long MRK versus a basket of mega-cap growth (e.g., short QQQ or pair against a concentrated AI proxy) for a 3-6 month factor rotation trade; asymmetry favors MRK because downside is buffered by cash flow and yield while upside comes from multiple normalization.
• Buy MRK on pullbacks below the current forward multiple range with a 6-12 month horizon; target a modest rerating rather than heroics, and use the dividend as carry while waiting for sentiment to rotate.
• For event-driven biotech exposure, keep SMMT as a small call option-sized position only through the November PDUFA; treat it as a high-variance catalyst trade with defined downside, not a core holding.
• If owning SMMT, consider financing with a short in a broader biotech ETF or another late-stage single-asset name to isolate the idiosyncratic approval event and reduce sector beta.
• Use any healthcare strength to trim overextended growth exposure rather than chase the sector broadly; the highest-probability outcome is relative outperformance, not a straight-line healthcare bull market.